Sarepta Therapeutics, Inc. Q4 and Full-Year 2022 Earnings Conference Call Forward Looking Statements

Tuesday, February 28, 2022 – 4:30 p.m. Eastern Time

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities, research and development programs, and the potential benefits of our product candidates; our 2023 net product revenue guidance for PMO of greater than $925 million and our belief that fluctuations and seasonality for ex-US orders will continue going forward; the potential benefits of rh74 and MHCK7; the potentially transformative benefits of SRP-9001, including our goal to change the course of Duchenne by treating the underlying cause of Duchenne with the one-time gene therapy that delivers functional dystrophin to muscle; our belief that, for SRP-9001, the levels of dystrophin expressed, based on vast clinical evidence and experience, are reasonably likely to predict clinical benefit in patients with Duchenne; our understanding that the FDA is not holding an Advisory Committee; our belief that 2023 will be the most eventful year in our company's history; the potential for our BLA for SRP-9001 to be a bellwether moment for patients living with Duchenne and for the promise of gene therapy as a class to deliver meaningful improvements in the lives of patients; our expectation from our informal discussions with the Division that there are no significant safety issues identified in our SRP-9001 BLA; our belief that OTP will enhance reviews and accelerate the transformative potential of cell and gene therapy and be a potentially great benefit to patients; and expected timelines, plans and milestones, including answering remaining questions from the FDA on our BLA for SRP-9001, preparing and managing pre-approval inspections related to a potential approval of SRP-9001, building inventory for a potential launch of SRP-9001 and completing launch readiness for the same, our PDUFA date of May 29, 2023 for SRP-9001, starting our ENVISION study for non-ambulant (Study 303) for SRP-9001, starting two separate studies with alternative approaches to removing pre-existing antibodies to potentially make SRP-9001 available to rh74 nAb positive patients; completing enrollment of MOMENTUM this quarter, discussing a filing for SRP-5051, if MOMENTUM is successful in the readout later this year, a data readout for EMBARK in the fourth quarter of 2023, potentially receiving insights from our VOYAGENE study into a broader patient population as we finalize plans for a global, phase 3 study using commercially representative process material that we intend to begin later this year for SRP-9003, commencing a systemic pilot study for SRP-6004, and announcing data from MOMENTUM toward the back half of 2023.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to sales of our products or attain the anticipated net revenues, profitability or positive cash-flow from operations; we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business, as well as the development of our product candidates and our financial and contractual obligations; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for SRP-5051, SRP-9001, the LGMD programs, including SRP-9003, and/or other programs may not be sufficient for obtaining regulatory approval; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; the commencement and completion of our clinical trials and announcement of results may be delayed or prevented for a number of reasons, including, among others, denial by the regulatory agencies of permission to proceed with our clinical trials, or placement of a clinical trial on hold, challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials and inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials of our product candidates are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; if the actual number of patients living with the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates, and the ongoing COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.